$NWBO, 50%+ downside is on the cards in the next month or two as efficacy concerns loom. Tax loss selling approaching next month. Then around mid 2027 one can expect a request for increase in billion odd shares. That would again be an excellent opportunity to make easy money! ;)
65
NHSBT announces collaboration with companies during various development phase including early clinical trials. Check out NephStrom & Orbsen Therapeutics. Both are cell therapy companies with NHSBT collaboration agreement for many years but no approvals. Sure there are more! $NWBO
189
If MHRA grants conditional approval at some point in 2027 and the stock spikes to $0.30–$0.40 that would create a decent short opportunity. Even better if it rallies to $0.50–$0.60. This provides even greater return on both sides. $NWBO 2/3
2
409
With limited commercial prospects, ongoing cash burn, & LP's track record of dilution & missed expectations, a slide back below $0.10 within a couple quarters is something you can absolutely count on. Get ahead of LP’s excuses, flawed execution & predatory financiers! $NWBO 3/3
3
454
Jordan retweeted
You only shitpost on NWBO. And only started existing last month. You have a wealth of long term information on the company for some reason. But decided to start commenting 30 days ago nonstop. And apparently now you know about current financiers actions. Settle down AF. Lmao. Lmao. 😂😂
$NWBO In its October 26 PR, NWBO identified 2 priorities: (1) expanding manufacturing capacity, including restarting US production as UK backup, &(2) preparing trials for cancers beyond GBM.
The glaring omission? No mention of preparing a US FDA BLA for DCVax-L. Why? 1/4
4
1
967
Instead, could the focus on US backup capacity & additional trials suggest management anticipates very restricted/conditional UK approval at best, potentially requiring further clinical evidence generation?
That could explain the apparent lack of US BLA preparations. 3/4
1
132
If MHRA (most supportive RA) still has efficacy concerns, FDA would likely reject. Otherwise, seeking revenue from the biggest & most profitable market by far would be the highest priority rather than running another trial when you’ve been diluting endlessly in pennies. $NWBO
152
$NWBO Flipper on iHub BSing about a new hire Michael Frank Vasilios. Apparently he works for Donohoe Advisory Associates, & is just a consultant to NWBO. They had consultants who were experts with NYSE before and it lead to nothing. Flipper has a 13+ year history of BS & lies.
148


